Navigation Links
Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study
Date:9/6/2012

THURSDAY, Sept. 6 (HealthDay News) -- A new review finds that rheumatoid arthritis medications known as biologics don't raise the risk of cancer, contrary to what some previous research has suggested.

Rheumatoid arthritis affects an estimated 1 percent of the general population, with women three times more likely to have it. Different from age-related osteoarthritis, rheumatoid arthritis is debilitating autoimmune disorder that causes inflammation of the lining of the joints.

Biologics work by targeting specific parts of the immune system involved in the inflammation process.

Previous studies have raised questions about whether the drugs might boost the risk of cancer. The new study appears in the Sept. 5 issue of the Journal of the American Medical Association.

The researchers, led by a researcher at the University of Texas M.D. Anderson Cancer Center, looked at 63 randomized controlled trials of the drugs that featured follow-up periods of at least 24 weeks. In total, the studies analyzed nearly 29,500 patients.

The biologic medications are abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), rituximab (Rituxan), and tocilizumab (Actemra).

The analysis didn't find any extra risk of cancer compared to other drugs for rheumatic arthritis or a placebo.

The drugs are commonly used to treat rheumatoid arthritis, said Dr. Nadera Sweiss, an associate professor of medicine at the University of Illinois at Chicago College of Medicine who was not involved with the study.

"Biologic therapy revolutionized the treatment of [rheumatoid arthritis]," she said, and explained that these drugs are "introduced earlier in the disease course to control inflammatory activity early on and decrease the risk of disability."

Fear of cancer, however, has been a major issue for patients, she said, especially in those who may need to be on the medications for life.

As for the new analysis, she praised it but said it's limited because it examines the effect of the drugs up to 24 weeks. "There is still a concern about long-term safety," she said.

More information:

For more about rheumatoid arthritis, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Nadera Sweiss, M.D., associate professor, medicine, University of Illinois at Chicago College of Medicine; Sept. 5, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
7. Older Antipsychotics May Work as Well as Newer Ones: Review
8. Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
9. Newer Drug-Releasing Stent Cuts Chances of Cardiac Events: Study
10. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
11. Treat Rheumatoid Arthritis Early and Aggressively: Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Rheumatoid Arthritis Drugs Don't Raise Cancer Risk: Study
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed ... stem cell therapy technology, protocols and patient results as have been achieved with ... a more accessible standard of care for patients worldwide. , As the Medical Advisory ...
(Date:5/24/2016)... ... 24, 2016 , ... Loma Linda University Health (LLUH) has officially broken ground ... Hospital. Over 3,000 people looked on as the shovels hit the dirt at the ... , During the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Boyd Industries, a ... Delivery Unit® (CDU), a groundbreaking new product for pediatric dentistry , at AAPD ... in San Antonio, TX May 26-29. The Concealed Delivery Unit keeps dental hand pieces ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that improving life ... trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged – Insights ... the creative use of mobile digital devices can be an effective tool to help ...
(Date:5/24/2016)... ... 24, 2016 , ... Growing in popularity, more and more people continue to ... and easily accessible. Whether someone chooses to cut gluten out of their life for ... Kullen Grocery stocks their shelves with many different gluten-free products all year round. And ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... May 23, 2016 Non-invasive diagnostic ... of multiple diseases; ,Technology to be presented at Yissum’s ... Yissum Research Development Company of the Hebrew University of ... research agreement with Aurum Ventures MKI, the technology investment arm ... a new diagnostic approach for early detection of multiple ...
(Date:5/22/2016)... May 23, 2016 DS ... anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive ... non-alcoholic steatohepatitis (NASH) patients. Recent DS ... in lung tissue and has bronchodilatory, anti-inflammatory and ... administration. The Company will publish further detail on ...
(Date:5/20/2016)... ReportsnReports.com adds "Plaque Psoriasis ... research report with comprehensive information on the therapeutic ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
Breaking Medicine Technology: